Phase 3 CNS Clinical Trials

5 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–5 of 5 trials

Recruiting

Phase 3

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

Shanghai Shengdi Pharmaceutical Co., Ltd250 enrolled2 locationsNCT07275814

Recruiting

Phase 2Phase 3

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

Known or Highly Suspected Central Nervous System (CNS) LesionKnown or Highly Suspected Body (Excluding CNS) Lesion

GE Healthcare640 enrolled1 locationNCT07472491

Recruiting

Phase 3

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)

Shanghai Shengdi Pharmaceutical Co., Ltd306 enrolled2 locationsNCT07275723

Recruiting

Phase 3

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Demyelinating DiseasesMultiple SclerosisNervous System Diseases+3 more

Amsterdam UMC, location VUmc200 enrolled1 locationNCT05834855

Completed

Phase 3

A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.

Central nervous system diseases requiring a contrast-enhanced MRI of the CNS.

Bayer Australia Ltd402 enrolled7 locationsACTRN12608000455369